Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jul. 01, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,133	$ 8,524
Accounts receivable, less allowances of $180 and $189	8,019	8,115
Inventories	5,655	5,634
Contract assets, net	1,467	1,312
Other current assets	1,721	1,644
Total current assets	19,995	25,229
Property, plant and equipment, net	9,292	9,280
Acquisition-related intangible assets, net	17,437	17,442
Other assets	4,108	4,007
Goodwill	43,273	41,196
Total assets	94,105	97,154
Current liabilities:
Short-term obligations and current maturities of long-term obligations	4,814	5,579
Accounts payable	2,423	3,381
Accrued payroll and employee benefits	1,310	2,095
Contract liabilities	2,590	2,601
Other accrued expenses	2,975	3,354
Total current liabilities	14,112	17,010
Deferred income taxes	2,842	2,849
Other long-term liabilities	4,042	4,238
Long-term obligations	29,194	28,909
Redeemable noncontrolling interest	113	116
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued	0	0
Common stock, $1 par value, 1,200,000,000 shares authorized; 441,398,059 and 440,668,112 shares issued	441	441
Capital in excess of par value	17,030	16,743
Retained earnings	44,289	41,910
Treasury stock at cost, 55,448,286 and 50,157,275 shares	(15,084)	(12,017)
Accumulated other comprehensive income/(loss)	(2,924)	(3,099)
Total Thermo Fisher Scientific Inc. shareholders’ equity	43,752	43,978
Noncontrolling interests	50	54
Total equity	43,802	44,032
Total liabilities, redeemable noncontrolling interest and equity	$ 94,105	$ 97,154